Language

English

Publication Date

9-11-2023

Journal

Clinical Infectious Diseases

DOI

10.1093/cid/ciad233

PMID

37078720

PMCID

PMC10495124

PubMedCentral® Posted Date

4-20-2023

PubMedCentral® Full Text Version

Post-print

Abstract

We administered severe acute respiratory syndrome coronavirus-2 viral-specific T cells (VSTs) under emergency investigational new drug applications to 6 immunocompromised patients with persistent coronavirus disease 2019 (COVID-19) and characterized clinical and virologic responses. Three patients had partial responses after failing other therapies but then died. Two patients completely recovered, but the role of VSTs in recovery was unclear due to concomitant use of other antivirals. One patient had not responded to 2 courses of remdesivir and experienced sustained recovery after VST administration. The use of VSTs in immunocompromised patients with persistent COVID-19 requires further study.

Keywords

Humans, SARS-CoV-2, COVID-19, T-Lymphocytes, Immunocompromised Host, Hematopoietic Stem Cell Transplantation, COVID-19, immunocompromised, prolonged infection, T cell

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.